XERS - Xeris Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.11
+0.43 (+4.03%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close10.68
Open10.59
Bid0.00 x 900
Ask0.00 x 900
Day's Range10.34 - 11.21
52 Week Range6.85 - 27.98
Volume187,392
Avg. Volume186,941
Market Cap299.306M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.22
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.00
Trade prices are not sourced from all markets
  • Business Wire7 days ago

    Xeris Pharmaceuticals Announces Additional Positive Outcomes from a Global Phase 3 Clinical Trial of Its Investigational Ready-to-Use Glucagon

    Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced positive findings from a global Phase 3 trial of its ready-to-use (RTU) room-temperature stable liquid glucagon conducted in Europe and North America. The Phase 3, multi-center, randomized controlled, non-inferiority study was conducted among 132 adults with type 1 diabetes to evaluate the Xeris RTU glucagon auto-injector as a treatment for severe hypoglycemic events as compared with Novo Nordisk’s GlucaGen® HypoKit®. The results demonstrated comparable efficacy between the two groups for achieving a plasma glucose of 70 mg/dl or ≥20 mg/dl increase in plasma glucose concentration within 30 minutes of glucagon administration.

  • Can We See Significant Institutional Ownership On The Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Share Register?
    Simply Wall St.last month

    Can We See Significant Institutional Ownership On The Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Share Register?

    A look at the shareholders of Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) can tell us which group is most powerful...

  • GlobeNewswire2 months ago

    Xeris Pharmaceuticals Announces First Quarter 2019 Financial Results and Highlights Its Pipeline

    Continuing to execute commercial build and launch readiness for Gvoke HypoPen™ and Gvoke PFS™ Dosed first patient in a Phase 2 study evaluating ready-to-use (RTU) glucagon in.

  • GlobeNewswire2 months ago

    Xeris Pharmaceuticals Announces Results From a Phase 1 Study of Its Novel Formulation of Diazepam

    The Phase 1, open-label, three-treatment, three-way crossover, randomized controlled study was conducted among 24 healthy volunteers to assess the bioavailability and pharmacokinetics (PK) of Xeris’ novel formulation of diazepam after intramuscular (IM) and subcutaneous (SC) administration compared to an administration of commercial diazepam rectal gel (Diastat®). Secondary objectives were to assess the safety and tolerability of Xeris’ diazepam after SC and IM administration.

  • GlobeNewswire2 months ago

    Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on April 24, 2019, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 73,000 shares of its common stock to eight new employees under Xeris’ Inducement Equity Plan. Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

  • GlobeNewswire3 months ago

    Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    CHICAGO, March 29, 2019 -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize.

  • Business Wire3 months ago

    Xeris Pharmaceuticals Presents New Clinical and Economic Impact Data on Its Developmental Ready-to-Use Glucagon

    Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced it is presenting data on its developmental ready-to-use (RTU) room-temperature stable liquid glucagon at two medical conferences. “Our R&D efforts continue to provide support for the value of our novel formulation technology platform for not only patients and providers, but for payers and healthcare systems as well,” said Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals.

  • Business Wire3 months ago

    Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia

    Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has now begun dosing patients in a Phase 2 trial with its ready-to-use, room-temperature stable liquid glucagon in patients with Type 1 diabetes who experience episodes of exercise-induced hypoglycemia (EIH). “Many individuals with diabetes treated with insulin experience EIH and the complexity of managing it is a major barrier to the adoption of regular physical activity.

  • How Many Insiders Bought Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Shares?
    Simply Wall St.3 months ago

    How Many Insiders Bought Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insidersRead More...

  • GlobeNewswire4 months ago

    Xeris Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline Progress

    Continuing to execute commercial build and launch readiness for Gvoke HypoPen™ Advancing pipeline of preclinical and clinical development-stage products Cash position of.

  • GlobeNewswire4 months ago

    Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on February 27, 2019, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 65,000 shares of its common stock to three new employees under Xeris’ Inducement Equity Plan. Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

  • GlobeNewswire4 months ago

    Xeris Pharmaceuticals to Participate at SVB Leerink Global Healthcare Conference

    Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference. A live webcast of the fireside chat can be accessed by visiting ‘Upcoming Events’ in the Investors section on the Company's website at www.xerispharma.com.

  • GlobeNewswire4 months ago

    Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock

    CHICAGO, Feb. 13, 2019 -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize.

  • Why Molson Coors Brewing, Xeris Pharmaceuticals, and Varonis Systems Slumped Today
    Motley Fool4 months ago

    Why Molson Coors Brewing, Xeris Pharmaceuticals, and Varonis Systems Slumped Today

    Even with the market rising, these companies suffered from bad news.

  • Benzinga4 months ago

    The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 11) Boston Scientific Corporation (NYSE: BSX ) Inspire ...

  • GlobeNewswire4 months ago

    Xeris Pharmaceuticals Announces Proposed Public Offering of Shares of Common Stock

    Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it filed a registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) relating to a proposed public offering of 5,000,000 shares of its common stock. All shares of common stock will be offered by Xeris.  Xeris expects to grant the underwriters a 30-day option to purchase up to an additional 750,000 of the shares of common stock.

  • Business Wire6 months ago

    European Medicines Agency Grants Orphan Drug Designation for Xeris’ Investigational Ready-to-Use Glucagon for the Treatment of Non-Insulinoma Pancreatogenous Hypoglycaemia Syndrome (NIPHS)

    Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced today that it has received Orphan Medicinal Product designation from the European Medicines Agency (EMA) for its investigational ready-to-use liquid glucagon as a treatment for non-insulinoma pancreatogenous hypoglycaemia syndrome (NIPHS), a spectrum of metabolic conditions, which includes post-bariatric hypoglycemia (PBH). A similar orphan designation was granted by the United States Food and Drug Administration (FDA) in January 2018.

  • GlobeNewswire8 months ago

    Xeris Pharmaceuticals Announces Third Quarter 2018 Financial Results and Highlights Pipeline Progress

    Glucagon pen NDA accepted for review by FDA Continuing to execute commercial build and launch readiness for glucagon pen Advancing pipeline of preclinical and clinical.

  • Business Wire8 months ago

    Xeris Pharmaceuticals Announces FDA Acceptance for Review of NDA for Its Ready-to-Use Glucagon Rescue Pen

    Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced today that its new drug application (NDA) for its ready-to-use, room-temperature stable liquid glucagon rescue pen for the treatment of severe hypoglycemia in people with diabetes has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA has assigned a PDUFA (Prescription Drug User Fee Act) goal date for completion of the review of the glucagon rescue pen NDA of June 10, 2019.

  • Business Wire10 months ago

    Xeris Pharmaceuticals and OHSU Conducting Artificial Pancreas Clinical Trial Using Xeris’ Novel Ready-to-Use Liquid Glucagon

    Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced today that Jessica Castle, M.D., an associate professor of medicine in the OHSU School of Medicine and OHSU Harold Schnitzer Diabetes Health Center in Portland, Oregon, is conducting a clinical trial with a dual-hormone artificial pancreas using Xeris’ ready-to-use liquid glucagon to evaluate a new closed-loop algorithm.

  • Business Wirelast year

    Xeris Pharmaceuticals Announces Positive Phase 3 Clinical Trial Data on Its Investigational Ready-to-Use Glucagon Rescue Pen

    Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced the presentation of positive results from two of its Phase 3 clinical studies on its investigational ready-to-use, room-temperature stable liquid glucagon rescue pen during oral and poster sessions at the American Diabetes Association’s (ADA) 78th Scientific Sessions, June 22-26, 2018. The data presentations highlight the efficacy and safety data from studies of the Xeris ready-to-use glucagon rescue pen in treating severe hypoglycemia in adults and children with type 1 diabetes, as compared to the currently marketed Glucagon Emergency Kit (GEK).